The Nutriventia Ndude Labs investment, structured as an allotment of equity shares, has closed with two prominent law firms steering the parties through the transaction. Stratage Law Partners advised Nutriventia Private Limited, while Cyril Amarchand Mangaldas advised Ndude Labs on the deal. The fresh capital is set to accelerate Nutriventia’s clinical research, branded ingredients portfolio, and US commercial expansion.
Introduction
Nutriventia Private Limited, a science-led Indian nutraceutical ingredients company specialising in clinically validated, proprietary branded ingredients, has closed a strategic growth investment from NDude Labs, a strategic investment firm. The transaction comprised a primary subscription to equity shares, resulting in the investor acquiring a 33% stake on a fully diluted basis, and involved the negotiation and implementation of the investment, governance, shareholder rights, and exit framework governing the company and its founders.
Nutriventia is engaged in the business of manufacturing and B2B supply of nutraceutical ingredients and dietary supplement ingredients. NDude Labs is an investment firm operating in India and the US. The financial terms of the investment were not disclosed.
Legal Teams Involved
Stratage Law Partners — Advising Nutriventia Private Limited
Stratage Law Partners advised Nutriventia on this transaction. The firm’s role included reviewing, negotiating, and finalisation of the transaction documents, along with the finalisation of conditions precedent and closing actions.
- Darshan Upadhyay — Managing Partner
- Soumya Shanker — Partner
- Abhay Gaur — Senior Associate
- Gaurav Deep Agrawal — Associate
Cyril Amarchand Mangaldas — Advising Ndude Labs
Cyril Amarchand Mangaldas advised NDude Outpost 1 on its maiden equity investment in Nutriventia Private Limited.
- Bhargav Joshi — Partner
- SB Aditi — Associate
- Ratna Pandey — Associate
- Swati Sharma — Partner, Head – Intellectual Property
- Gitika Suri — Director – Patents
- Animesh Srivastava — Associate
Significance and Impact
The fresh capital will allow the company to expand clinical R&D, its branded portfolio and US commercial operations. Specifically, the capital will deepen Nutriventia’s clinical R&D and expand its portfolio of proprietary branded ingredients — TurmXTRA, CaffXtend, C-Fence, Melotime, Ashwanova (Prolanza), and ALAXTRA.
Nutriventia’s ingredients already reach formulators and wellness brands across the United States, Europe, Australia, South Korea, and Japan. The transaction is also notable for its IP dimension: the inclusion of a dedicated intellectual property advisory sub-team within the CAM mandate signals the strategic importance of Nutriventia’s proprietary delivery technology to the overall deal structure.
The investment reflects a broader shift in the nutraceutical industry, as international brands move from commodity supply toward clinically validated, evidence-backed formulations. For Stratage Law Partners, the mandate demonstrates the firm’s growing presence in cross-border healthcare and life-sciences transactions. For Cyril Amarchand Mangaldas, the deal adds to its established record of advising growth-stage investors entering India’s fast-expanding nutraceuticals sector.
For a broader view of law firm deal activity, see the Deal Meter.
The Nutriventia Ndude Labs investment marks a significant equity milestone for one of India’s emerging science-led nutraceutical ingredient companies, with a clear mandate to scale globally. The transaction’s governance and shareholder rights framework, negotiated as part of the closing, reflects the structured approach increasingly expected in growth-stage healthcare deals. With two top-tier legal advisors at the table, the deal underscores the maturing legal infrastructure supporting India’s nutraceutical and life-sciences investment ecosystem.
Disclaimer: This article is for informational purposes only and does not constitute legal advice. It is based on the details provided and publicly available sources.
